Company Quick10K Filing
Magna Lab
Price-0.00 EPS-0
Shares1 P/E0
MCap-0 P/FCF0
Net Debt-0 EBIT-0
TEV-0 TEV/EBIT0
TTM 2019-05-31, in MM, except price, ratios
10-Q 2020-05-31 Filed 2020-07-20
10-K 2020-02-29 Filed 2020-06-25
10-Q 2019-11-30 Filed 2020-01-13
10-Q 2019-08-31 Filed 2019-10-11
10-Q 2019-05-31 Filed 2019-07-11
10-K 2019-02-28 Filed 2019-06-12
10-Q 2018-11-30 Filed 2019-01-11
10-Q 2018-08-31 Filed 2018-10-12
10-Q 2018-05-31 Filed 2018-07-16
10-K 2018-02-28 Filed 2018-06-13
10-Q 2017-11-30 Filed 2018-01-16
10-Q 2017-08-31 Filed 2017-10-16
10-Q 2017-05-31 Filed 2017-07-14
10-K 2017-02-28 Filed 2017-06-14
10-Q 2016-11-30 Filed 2017-01-13
10-Q 2016-08-31 Filed 2016-10-12
10-Q 2016-05-31 Filed 2016-07-12
10-K 2016-02-29 Filed 2016-06-10
10-Q 2015-11-30 Filed 2016-01-14
10-Q 2015-08-31 Filed 2015-10-06
10-Q 2015-05-31 Filed 2015-07-09
10-K 2015-02-28 Filed 2015-06-15
10-Q 2014-11-30 Filed 2015-01-14
10-Q 2014-08-31 Filed 2014-10-17
10-Q 2014-05-31 Filed 2014-06-23
10-K 2014-02-28 Filed 2014-06-06
10-Q 2013-11-30 Filed 2014-01-13
10-Q 2013-08-31 Filed 2013-10-03
10-K 2013-02-28 Filed 2013-06-12
10-Q 2012-11-30 Filed 2013-01-16
10-Q 2012-08-31 Filed 2012-10-16
10-Q 2012-05-31 Filed 2012-07-12
10-K 2012-02-29 Filed 2012-06-11
10-Q 2011-11-30 Filed 2012-01-12
10-Q 2011-08-31 Filed 2011-10-11
10-Q 2011-05-31 Filed 2011-07-14
10-K 2011-02-28 Filed 2011-06-14
10-Q 2010-11-30 Filed 2011-01-13
10-Q 2010-08-31 Filed 2010-10-12
10-Q 2010-05-31 Filed 2010-07-14
10-K 2010-02-28 Filed 2010-06-16
10-Q 2009-11-30 Filed 2010-01-14
8-K 2020-07-02 Enter Agreement, Control, Exhibits
8-K 2020-05-29

MAGAA 10Q Quarterly Report

Part I: Financial Information
Item 1. - Financial Statements
Note 1 - Organization and Description of The Business
Note 2 - Summary of Significant Accounting Policies
Note 3 - Notes Payable and Accrued Interest - Related Party
Note 4 - Accounts Payable and Accrued Expenses
Note 5 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4T. Controls and Procedures
Part II - Other Information
Item 1A. Risk Factors
Item 3. Defaults Upon Senior Securities
Item 6. - Exhibits
EX-31.1 e619787_ex31-1.htm
EX-31.2 e619787_ex31-2.htm
EX-32.1 e619787_ex32-1.htm
EX-32.2 e619787_ex32-2.htm

Magna Lab Earnings 2020-05-31

Balance SheetIncome StatementCash Flow
0.1-0.3-0.6-1.0-1.3-1.72012201420172020
Assets, Equity
0.0-0.0-0.1-0.1-0.2-0.22012201420172020
Rev, G Profit, Net Income
0.10.10.0-0.0-0.1-0.12012201420172020
Ops, Inv, Fin

10-Q 1 e619787_10q-magna.htm

 

U.S. SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: May 31, 2020

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to ______

 

Commission File Number 0-21320

 

Magna-Lab Inc.

(Exact name of registrant as specified in its charter)

 

  New York   11-3074326  
  (State or other jurisdiction of incorporation or organization)   (IRS Employer Identification No.)  

 

 

  1185 Avenue of the Americas, 3rd Fl. New York NY 10036  
  (Address of principal executive offices and Zip code)  
     
  (646) 768-8417  
  (Issuer's telephone number including area code)  

 

     
  (Former name, former address and former fiscal year, if changed since last report)  

 

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐
(Do not check if a smaller reporting company)
Smaller reporting company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒  No ☐

 

APPLICABLE ONLY TO CORPORATE ISSUERS

 

State the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date – July 14, 2020

 

  Class A Common Stock, $.001 Par Value   1,178,762  
  Class B Common Stock, $.001 Par Value   567  
  Class   Shares  

 

 

MAGNA-LAB INC. AND SUBSIDIARY

 

CONTENTS

  

PART 1 – FINANCIAL INFORMATION  
     
  Item 1. – Financial Statements  
     
         Condensed Consolidated Balance Sheets 1
     
         Condensed Consolidated Statements of Operations (unaudited) 2
     
         Condensed Consolidated Statements of Cash Flows (unaudited) 3
     
         Condensed Consolidated Statements of Stockholders’ Deficit (unaudited) 4
     
         Notes to Condensed Consolidated Financial Statements (unaudited) 5 - 9
     
  Item 2. – Management’s Discussion and Analysis of Financial Condition And Results of Operations 10 - 11
     
  Item 3. – Quantitative and Qualitative Disclosures about Market Risk 12
     
  Item 4T. – Controls and Procedures 12
     
PART II - OTHER INFORMATION  
     
  Item 1A. – Risk Factors 12
     
  Item 3. – Defaults Upon Senior Securities 13
     
  Item 6. – Exhibits 13
     
SIGNATURES 14

 

All items which are not applicable or to which the answer is negative have been omitted from this report.

 

 

PART I: FINANCIAL INFORMATION

 

Item 1. - Financial Statements

 

MAGNA-LAB, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   May 31, 2020  February 29,
   2020  2020
   (unaudited)   
ASSETS      
       
Current assets          
      Cash  $   $1,000 
         Total current assets       1,000 
Total Assets  $   $1,000 
           
           
LIABILITIES & STOCKHOLDERS' DEFICIT          
           
Current liabilities          
Notes payable and accrued interest to related parties  $1,435,000   $1,406,000 
Accounts payable   352,000    353,000 
Accrued expenses and other current liabilities   45,000    40,000 
         Total current liabilities   1,832,000    1,799,000 
Total Liabilities   1,832,000    1,799,000 
           
Commitments and contingencies        
           
Stockholders' Equity          
Preferred stock, par value $0.01 5,000,000 shares authorized          
none issued and outstanding        
Common stock, Class A, par value $0.001; 120,000,000 shares authorized,          
1,178,762 shares issued and outstanding at May 31, 2020 and February 29, 2020   1,000    1,000 
Common stock, Class B, par value $0.001; 3,750,000 shares authorized,          
567 shares issued and outstanding at May 31, 2020 and February 29, 2020        
Additional paid-in capital   27,290,000    27,290,000 
Retained earnings (deficit)   (29,123,000)   (29,089,000)
Total Stockholders' Equity (Deficit)   (1,832,000)   (1,798,000)
Total Liabilities and Stockholders' (Equity)  $   $1,000 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 1

 

MAGNA-LAB AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   Three months ended
   May 31,  May 31,
   2020  2019
       
Revenue  $   $ 
           
Operating Expenses:          
     General & administrative   7,000    8,000 
     Total operating expenses   7,000    8,000 
Loss from operations   (7,000)   (8,000)
           
Other income (expense)          
     Interest (expense)   (27,000)   (26,000)
         Other income (expense) net   (27,000)   (26,000)
Income (loss) before provision for income taxes   (34,000)   (34,000)
Provision (credit) for income tax        
Net (loss)  $(34,000)  $(34,000)
           
Basic and diluted earnings(loss) per common share  $(0.03)  $(0.03)
           
Weighted average number of shares outstanding   1,179,000    1,179,000 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 2

 

MAGNA-LAB AND SUBSIDIARY

CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS

(UNAUDITED)

 

   Three months ended
   May 31,  May 31,
   2020  2019
Cash Flows From Operating Activities:          
Net (loss)  $(34,000)  $(34,000)
Adjustments to reconcile net income to net cash          
provided by (used for) operating activities          
Accounts payable and accrued expense   30,000    26,000 
Net cash used in operating activities   (4,000)   (8,000)
           
Cash Flows From Investing Activities:          
Net cash provided by (used for) investing activities        
           
Cash Flows From Financing Activities:          
Proceeds from notes payable to stockholder   3,000    10,000 
Net cash provided by financing activities   3,000    10,000 
           
Net Increase (Decrease) In Cash   (1,000)   2,000 
Cash At The Beginning Of The Period   1,000    4,000 
Cash At The End Of The Period  $   $6,000 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $   $ 
Cash paid for income taxes  $   $ 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 3

 

MAGNA LAB AND SUBSIDIARY CONDENSED

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

FOR THE THREE MONTHS ENDED MAY 31, 2020 AND MAY 31, 2019 (UNAUDITED)

 

   Common Stock Class A  Common Stock Class B  Paid in  Retained earnings  Equity/
   Shares  Value  Shares  Value  Capital  (Deficit)  Deficit
Balances,  February 28, 2019   1,178,762   $1,000    567   $   $27,290,000   $(28,955,000)  $(1,664,000)
                                    
Net (loss)                            (34,000)   (34,000)
                                    
Balances at May 31, 2019   1,178,762   $1,000    567   $   $27,290,000   $(28,989,000)  $(1,698,000)
                                    
Balances,  February 29, 2020   1,178,762   $1,000    567   $   $27,290,000   $(29,089,000)  $(1,798,000)
                                    
Net (loss)                            (34,000)   (34,000)
                                    
Balances at May 31, 2020   1,178,762   $1,000    567   $   $27,290,000   $(29,123,000)  $(1,832,000)

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 4

 

MAGNA-LAB INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE-MONTH PERIODS ENDED MAY 31, 2020 AND 2019

(Unaudited)

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS

 

Company Activities

 

Magna-Lab, Inc. (the “Company”), a New York corporation, is focused on effecting a “reverse merger,” capital exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more unrelated businesses (the “Business Combination”) that would benefit from the Company’s public reporting status. The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. As of May 31, 2020, the Company had not yet commenced any operations. All activity through May 31, 2020 also relates to preserving cash, making settlements with creditors, attempting to raise capital, and continuing the Company’s public reporting.

 

The Company’s subsidiary is Cardiac MRI, Inc., a wholly owned subsidiary of the Company.

  

The Company was previously engaged in research, development, and commercialization activities until it ceased such activities during the period September 2002 through March 2003. The Company’s efforts to raise additional capital or enter into a strategic arrangement in order to complete commercialization of its cardiac diagnostic Illuminator products and development of its Artery View product or to seek other means to realize value through sale, license or otherwise have been unsuccessful and therefore, in January 2017, the Company sold such technology to its President and CEO in exchange for relief from certain liabilities.

 

COVID-19

 

On March 11, 2020, the World Health Organization (“WHO”) declared the Covid-19 outbreak to be a global pandemic. In addition to the devastating effects on human life, the pandemic is having a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. Most US states and many countries have issued policies intended to stop or slow the further spread of the disease.

 

Covid-19 and the U.S. response to the pandemic are significantly affecting the economy. There are no comparable events that provide guidance as to the effect the Covid-19 pandemic may have, and, as a result, the ultimate effect of the pandemic is highly uncertain and subject to change. We do not yet know the full extent of the effects on the economy, the markets we serve, our business, or our operations.

 

 5

 

NOTE 2SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Management’s Representation of Interim Financial Statements

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X for smaller reporting companies and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). All adjustments which are of a normal recurring nature and, in the opinion of management, necessary for a fair presentation have been included. These interim unaudited condensed consolidated financial statements should be read in conjunction with the more complete information and the Company’s audited consolidated financial statements and related notes thereto included in the Company's annual report on Form 10-K for the year ended February 29, 2020. The operating results for the three months ended May 31, 2020, are not necessarily indicative of the results that may be expected for the year ending February 28, 2021.

   

Basis of Presentation and Principles of Consolidation

 

The consolidated financial statements of the Company have been prepared in accordance with GAAP. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses or recognized when incurred. The unaudited condensed consolidated financial statements include the accounts of Magna-Lab Inc. and its wholly-owned subsidiary, Cardiac MRI, Inc. (collectively, the “Company”) and all significant intercompany transactions and balances have been eliminated in consolidation.

 

Going Concern

 

As indicated in the accompanying interim unaudited condensed consolidated financial statements, at May 31, 2020, the Company had approximately $-0- of cash and negative working capital of approximately $1,832,000 and a stockholders’ deficit of approximately $1,832,000. These factors, among others, indicate that the Company requires additional financing or a strategic arrangement in order to continue its planned activities for the fiscal year that began on March 1, 2020. The Company’s plans to deal with this uncertainty are described above in “Company Activities.” Management’s plans to raise capital, enter into a strategic arrangement or sell or merge with an unrelated business have not been successful to date and there can be no assurance that management’s plans can be realized at all. Historically, substantially all of the Company’s financing, has come from shareholder loans. There can be no assurance that additional shareholder loans will be extended to the Company.

 

These factors, among others, raise substantial doubt about the Company’s ability to continue operations as a going concern. No adjustments have been made in the accompanying condensed consolidated financial statements to the amounts and classification of assets and liabilities which could result should the Company be unable to continue as a going concern.

 

The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these financial statements. On a consolidated basis, the Company has incurred significant operating losses since inception.

  

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

 

 6

 

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions every quarter to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit. Changes in the ownership of a majority of the fair market value of the Company's common stock would likely limit or eliminate the utilization of existing net operating loss carryforwards and credits. Although a formal Section 382 study to determine whether a change in control has occurred has not been completed, the Company believes, based upon limited analysis, that such changes may have occurred in 1997, 2000 and 2005. Such carryforwards and credits expire between 2019 and 2035. It is likely that any “reverse merger” or settlement of existing liabilities with equity or other strategic transaction is likely to result in a change in control under Section 382. See also Note 7 - Subsequent Events.

 

Net (loss) per share

 

The Company complies with the accounting and reporting requirements of U.S. GAAP with respect to computing its net loss per common share. Net loss per common share is computed based on the weighted average number of Class A Common and Class B Common shares outstanding.

 

Basic (loss) per share excludes dilution and is computed by dividing loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Since there are no options, warrants or derivative securities outstanding, basic and diluted (loss) per share were the same for the three-month periods ended May 31, 2020 and 2019.

 

Recently issued accounting standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying interim unaudited condensed consolidated financial statements.

  

NOTE 3 – NOTES PAYABLE AND ACCRUED INTEREST – RELATED PARTY

  

The balance of notes payable and accrued interest was approximately $1,435,000 and $1,406,000, as of May 31, 2020 and February 29, 2020, respectively. Notes payable include 12% unsecured notes payable to the Company’s principal stockholder, Magna Acquisition LLC (“MALLC”), a related party, in the aggregate principal amount of approximately $687,000, plus approximately $727,000 of interest accrued. In addition, notes payable include 10% unsecured notes payable to a director of the Company (who is also a manager of MALLC) in the aggregate principal amount of approximately $19,000 plus approximately $2,000 of accrued interest. All of such notes become due 120 days after issuance and, as such, approximately $687,000 principal amount of the MALLC notes are overdue at May 31, 2020. Approximately $17,000 of the notes payable to the director are overdue. The notes that are overdue bear interest at 15% and 12%, respectively, per year for the MALLC notes and for the director note subsequent to their maturity date. The noteholder has not asserted that the Company is in default.

 

Subsequent to May 31, 2020, in June 2020, the director loaned the Company an additional approximately $10,000.

 

The Company intends to make a proposal to this principal stockholder and to this director to convert all amounts outstanding to them (including overdue amounts) into common stock of the Company. See Note 5, Subsequent Events for discussion of the sale of these notes to a third party on July 2, 2020.

 

 7

 

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Some of the amounts recorded as accounts payable or accrued liabilities may have passed the statute of limitations for purposes of the counterparty seeking recovery of such monies. At May 31, 2020, the Company has not undertaken a formal study to evaluate recorded payables past the statute of limitations for purposes of possible write-off of such payables. See also, Note 7 – Subsequent Events.

 

Accrued expenses and other current liabilities includes approximately $18,000 due to a third party, guaranteed by our principal stockholder, for amounts paid to an account payable on our behalf. This amount is repayable if the proposed merger transaction with this party was not completed. This party subsequently merged with a third party and abandoned its possible transaction with the Company, however, there has not been a demand for repayment of this amount. The Company believes it would be entitled to an offset for recovery of certain costs from this third party associated with that proposed transaction pursuant to understandings between the parties.

  

NOTE 5- SUBSEQUENT EVENTS

 

On June 30, 2020 Joel S. Kanter, individually and as representative for (i) the 607,727 common shares of a Company owned by Magna Acquisition LLC (“Magna LLC”), (ii) the $1,453,811 of promissory notes owed by the Company to Magna LLC and to Joel S. Kanter (collectively, the “Notes”), and (iii) as representative for the four directors and/or officers owning 106,032 Class A common shares of MAGAA ( the “Seller”), entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) pursuant to which the Seller agreed to sell 202,576 Class A common shares and the Notes to Activist Investing LLC., an entity owned by David Lazar (the “Purchaser”) for $105,000. The 202,576 shares represent approximately 17.2% of the 1,179,329 Class A and Class B common shares of the Company’s outstanding common shares, which is not a majority. However, Mr. Lazar, who will become the Company’s sole director and officer on or about July 18, 2020, intends to cause the Purchaser to convert some or all of the Notes (which are currently not convertible) into enough common shares so the Purchaser will become the majority shareholder of the Company. As a result, on or about July 18, 2020, there will be a change of control of the Company. There is no family relationship or other relationship between the Seller and the Purchaser. An Amendment to the Stock Purchase Agreement clarified the responsibilities of the parties for filing tax returns, and that references to the Company included Cardiac MRI, Inc., the Company’s 100% subsidiary.

 

In connection with the sale under the Stock Purchase Agreement, the members of the Company’s Board of Directors have agreed to resign and appoint Mr. Lazar as the sole initial director of the Company, subject to the filing and dissemination of an Information Statement, which has taken place and the passage of the 10-day period set forth in SEC Rule 14f-1. The Company’s officers will also resign at the same time, namely Lawrence A. Minkoff, Ph.D., Chief Executive Officer and Kenneth C. Riscica, Treasurer, Secretary and Chief Financial Officer. As a result thereof, Lazar became the sole Director and officer of the Company.

 

Additionally, in connection with the closing of the Stock Purchase Agreement, the Seller agreed to pay approximately $37,000 to settle certain liabilities of the Company for stock transfer, Edgarizing and other services (approximately $18,000) and approximately $19,000 to settle a liability for the services of our Treasurer and Secretary (Chief Financial Officer) over an extended period of time aggregating approximately $186,000. Further, upon closing of the transaction, the Purchaser performed a review of certain accounts and accruals payable (approximately $173,000 and $18,000, respectively) and received a legal opinion that such outstanding accounts payable and accrued liabilities aggregating approximately $191,000 were time-barred by the Statute of Limitations and has recorded the relief of those liabilities, and a gain on debt extinguishment, as of the closing date of the transaction. A Summary Pro Forma Balance Sheet reflecting the effects of the transactions effected at the closing of the Stock Purchase Agreement is as follows:

 

 8

 

Summary Pro-Forma Balance Sheet at July 2, 2020

(dollars in '000's)

 

   May 31, 2020  Subsequent Activity  Note  Transaction Effects  Note  Pro Forma July 2, 2020
Cash and total assets  $0   $10,000   a.  $0      $0 
         (10,000)  b.             
   Total assets  $0   $0      $0      $0 
Liabilities:                         
Notes and interest to related parties  $1,435,000   $10,000   a.  $      $1,454,000 
         9,000   d.             
Accounts payable   352,000    12,000   c.   (192,000)  e.    
                 (172,000)  f.     
Accrued liabilities   45,000    (10,000)  b.   (12,000)  e.   5,000 
                 (18,000)  f.     
   Total liabilities   1,832,000    21,000       (394,000)      1,459,000 
                          
Equity (Deficit):                         
Common stock paid-in capital   27,290,000            186,000   e.   27,476,000 
Accumulated deficit   (29,122,000)   (9,000)  d.   18,000   e.   (28,935,000)
         (12,000)  c.   190,000   f.     
   Total stockholders' deficit   (1,832,000)   (21,000)      394,000       (1,459,000)
Total liabilities and equity  $0   $0      $0      $0 

 

Notes to Pro Forma:

Subsequent activity:

a.Represents loans from a director in June 2020.
b.Represents payment of expenses primarily for audit services in June 2020.
c.Represents expenses accrued in June 2020.
 d.Additional interest accrual on notes.

 

Transaction effects:

e.Liabilities of the Company paid and settled by the Seller.
f.Liabilities of the Company relieved.

 

 9

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

Forward Looking Statements

 

Some of the statements contained in this report discuss our plans and strategies for our business or state other forward-looking statements, as this term is defined in the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical facts may be deemed to be forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "plan," "intend," "should," "seek," "will," and similar expressions are intended to identify these forward-looking statements but are not the exclusive means of identifying them. These forward-looking statements reflect the current views of our management. However, various risks, uncertainties and contingencies could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, these statements. See our Form 10-K for the year ended February 29, 2020 for a discussion of certain known risks; also see Part II, Item 1A.

 

Overview, Background and History

 

We are currently a “shell company” with no meaningful assets or operations other than our efforts to identify and merge with an operating company. We no longer have any full-time employees and our Chief Executive and Chief Financial Officers serve on a part-time consulting basis.

 

Prior to March 2003, our business had been focused on pre-revenue development and commercialization of disposable medical devices designed to enhance the effectiveness of magnetic resonance imaging in detection and diagnosis of heart disease. Due to the unavailability of funding, beginning in the fall of 2002 we essentially ceased all of our operations including product development and commercialization activities. Our efforts to realize value for our prior business and MRI technology have been unsuccessful. As a result, we view our most viable option to be merging with an unrelated operating company that would benefit from our status as a reporting company in a so-called “reverse merger” transaction. Entering into a “reverse merger” would likely involve very substantial dilution to the existing stockholders. It would, however, provide an opportunity to return some value to stockholders. While we have identified and explored merging with a number of candidates over the past few years and entered into definitive agreements with one candidate (which agreement was subsequently terminated), we have no commitments to merge with any company at the present time.

 

In January 2017, the Company’s President and Chief Executive Officer (the “CEO”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with the Company. Under the Purchase Agreement, the CEO purchased all of the intellectual property rights, any and all physical assets, any and all permits and all non-financial books, records, files, design specification, software and other data related to the Company’s magnetic resonance imaging technology. In exchange for purchased assets, the CEO (a) assumed all liabilities of the Company related exclusively to the purchased assets and (b) agreed to forgiveness of all indebtedness owing from the Company totaling approximately $110,000 including intellectual property counsel fees and costs, $68,000 of which had been paid by and is therefore due to the CEO for payments he has made on the Company’s behalf in prior years in an attempt to preserve certain intellectual property rights at that time. The CEO ceased making such payments several years ago and, as such, the underlying intellectual property became compromised.

 

In order to raise cash to continue our efforts to pursue a reverse merger, on October 31, 2005, the Company consummated a stock purchase agreement with Magna Acquisition LLC (“MALLC”) which resulted in a change of control of our Company. Under the agreement, we sold 300,000 shares of Class A Common Stock to MALLC for gross proceeds of $190,000, before expenses. Contemporaneous with the new investment, MALLC purchased from our former principal stockholder 307,727 shares of the Company’s Class A Common Stock, representing all the shares of our common stock owned by that stockholder. Two of our directors and our Chief Financial Officer serve as sole managers of MALLC, with the ability to vote and dispose of the shares of our Company owned by MALLC by majority vote. These directors have assumed a lead role with management in pursuing financing and merger candidates and operating matters.

 

 10

 

MALLC has been responsible for substantially all of our funding since October 2005 and until June 30, 2020. During the period from October 2005 through and including May 31, 2020, MALLC loaned us an aggregate of approximately $687,000 under a series of promissory notes payable that mature 120 days from issuance. At May 31, 2020, approximately $687,000 face amount of such notes were beyond their maturity date and therefore due on demand. The notes bear interest at 12% per year increasing to 15% per year for periods beyond maturity. Since May 2019, a director of the Company loaned the Company approximately $29,000 (including approximately $10,000 loaned subsequent to May 31, 2020) under unsecured notes payable with substantially the same terms as the MALLC notes payable except that the interest rate decreased from 12% to 10% and the penalty interest rate decreased from 15% to 12%. The Company intends to make a proposal to MALLC and to this director to convert all of the amounts outstanding to them (including overdue amounts) into common stock of the Company.

 

While we have reduced our expenditures very significantly, we do not have sufficient cash to continue our activities for the coming twelve months. We currently do not have any commitments for new funding. Subsequent to May 31, 2020, on July 2, 2020 the Company's noteholders, MALLC and Joel Kanter, entered into an agreement to sell the notes payable by the Company to a third party as further described in Note 7 to Item 1. Financial Statements.

 

Recent Developments –

 

COVID-19

 

In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China, which has and is continuing to spread throughout other parts of the world, including the United States. On January 30, 2020, the World Health Organization declared the outbreak of the coronavirus disease (COVID-19) a “Public Health Emergency of International Concern.” On January 31, 2020, U.S. Health and Human Services Secretary Alex M. Azar II declared a public health emergency for the United States to aid the U.S. healthcare community in responding to COVID-19, and on March 11, 2020 the World Health Organization characterized the outbreak as a “pandemic.” COVID-19 has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide. The business of any potential target business with which we consummate a business combination could be materially and adversely affected. Furthermore, we may be unable to complete a business combination if continued concerns relating to COVID-19 restrict travel, limit the ability to have meetings with potential investors or the target company’s personnel, vendors and services providers are unavailable to negotiate and consummate a transaction in a timely manner. The extent to which COVID-19 impacts our search for a business combination will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. If the disruptions posed by COVID-19 or other matters of global concern continue for an extended period of time, our ability to consummate a business combination, or the operations of a target business with which we ultimately consummate a business combination, may be materially adversely affected.

 

Sale of Related Party Notes Payable; Change in Control –

 

Subsequent to May 31, 2020, on July 2, 2020 the Company's noteholders, MALLC and Joel Kanter, entered into an agreement to sell the notes payable by the Company to a third party as further described in Note 5 to Item 1. Financial Statements. Such sale of notes and stock is expected to result in a change in control of the Company as some or all of the notes are expected to be converted into shares of Class A common stock.

 

Results of Operations for the Three Months Ended May 31, 2020 compared to the three months ended May 31, 2019

 

We have neither engaged in any operations or generated any revenues during the three months ended May 31, 2020 and 2019. We incur expenses associated with being a public company including financial reporting and compliance and accounting and audit.

  

Operating expenses for three months ended May 31, 2020 were approximately $7,000 compared to $8,000 the three months ended May 31, 2019 due to comparable levels of activities on both periods. Interest expense was approximately $27,000 for the 2020 period compared to $26,000 during the same period ended May 31, 2019. The slight increase in interest expense was attributable to higher levels of borrowing for the period ended May 31, 2020.

 

During the three months ended May 31, 2020 we recorded a net loss of $34,000 compared to a net loss of $34,000 for the three months ended May 31, 2019.

 

Our expenses, particularly professional and consulting fees, can increase significantly if we are actively engaged in negotiations for a merger transaction. There can be no assurance that any of our activities will result in any transaction. Our interest expenses are increasing with additional outstanding borrowings

 

Financial Condition, Liquidity and Capital Resources

 

Going concern

 

As indicated in the accompanying interim unaudited condensed consolidated financial statements, at May 31, 2020, the Company had approximately $-0- of cash and negative working capital of approximately $1,832,000 and stockholders’ deficit of $1,832,000. These factors, among others, indicate that the Company is in need of additional financing or a strategic arrangement in order to continue its planned activities for the fiscal year that began on March 1, 2020. The Company’s plans to deal with this uncertainty are described above in “Company Activities.” Management’s plans to raise capital, enter into a strategic arrangement or sell or merge with an unrelated business have not been successful to date and there can be no assurance that management’s plans can be realized at all. Historically, substantially all of the Company’s financing, has come from shareholder loans. There can be no assurance that additional shareholder loans will be extended to the Company.

 

These factors, among others, raise substantial doubt about the Company’s ability to continue operations as a going concern. No adjustments have been made in the accompanying condensed consolidated financial statements to the amounts and classification of assets and liabilities which could result should the Company be unable to continue as a going concern.

 

Off Balance Sheet Arrangements

 

The Company has no material off balance sheet arrangements that are likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital resources or capital expenditures.

 

Critical Accounting Principles

 

The preparation of consolidated financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates. We have not identified any critical accounting policies.

  

 11

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Market risk is the sensitivity of income or loss to changes in interest rates, foreign exchanges, commodity prices, equity prices, and other market driven rates or prices. We are not presently engaged in any substantive commercial business. Accordingly, the risks associated with foreign exchange rates, commodity prices, and equity prices are not significant. Our debt obligations contain interest rates that are fixed and we do not enter into derivatives or other financial instruments for trading or speculative purposes.

 

Item 4T. Controls and Procedures

 

In June 2018, the Company’s auditors advised the Audit Committee that they believe that a material weakness in internal accounting controls exists by reason of the impact of the Company’s financial constraints on its ability to continue its timely public reporting as well as the lack of desirable segregation of duties, among other matters.  Based on this information, management has revised its conclusion on the adequacy of its disclosure controls and its internal accounting controls to that stated below.

 

(a) Evaluation of Disclosure Controls and Procedures.  The Company’s senior management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) designed to ensure that the information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

The Company has evaluated the effectiveness of the design and operation of its disclosure controls and procedures under the supervision of and with the participation of management, including the Chief Executive Officer and our Chief Financial Officer as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are not effective.

 

(b) Changes in Internal Control Over Financial Reporting. There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

There are inherent limitations in any system of internal control. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that its objectives are met. Further, the design of a control system must consider that resources are not unlimited and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgment in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.

 

PART II - OTHER INFORMATION

 


Item 1A. Risk Factors

 

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

 

 12

 

Item 3. Defaults Upon Senior Securities

 

As discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations – Overview, Background and History, $690,000 principal amount of 12% notes payable to Magna Acquisition LLC (“MALLC) are in default at May 31, 2020 as a result of their non-payment when due. Such notes now carry a default rate of interest of 15%. All of these notes were assigned to the Purchaser as part of the change of control described in Note 7-Subsequent Events.

 

Item 6. - Exhibits

 

31.1Certification of Principal Executive Officer pursuant to Exchange Act Rule 13a – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 13

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MAGNA-LAB INC.  
    (Registrant)  
       

Date: July 20, 2020

By: /s/ David Lazar  
   

David Lazar, CEO and CFO

 

  

 

INDEX TO EXHIBITS

  

No.

Description

  
31.1Certification of Principal Executive Officer pursuant to Exchange Act Rule 13a – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.